Nehmen Sie Kontakt auf.

Zur Kontaktliste

Haben Sie Fragen zu Services oder zum Literaturangebot von ZB MED? Benötigen Sie Tipps zur Recherche in LIVIVO?

Kontakt

info@zbmed.de
Telefonnummer: +49 (0)221 478-5685

Köln

Medizin und Gesundheitswesen

Adresse:
ZB MED – Informationszentrum Lebenswissenschaften
Gleueler Straße 60
50931 Köln

Bonn

Ernährungs-, Umwelt- und Agrarwissenschaften

Adresse:
ZB MED – Informationszentrum Lebenswissenschaften
Friedrich-Hirzebruch-Allee 4
53115 Bonn

InfoCenter

INFORMATION.

WISSEN.
LEBEN.

Infrastruktur- und Forschungszentrum für lebenswissenschaftliche Daten und Informationen.

Thema Lebenswissenschaften?

Wir haben die Werkzeuge für Ihre passgenauen Recherchen.

Kongressdetails

20.02.2019 - 21.02.2019

RNA Therapeutics 2019

Veranstaltungsort
Copthorne Tara Hotel London Kensington, Scarsdale Place, Greater London, W8 5SY
Kontakt und Ansprechparter

Pav Solanki

psolanki@smi-online.co.uk

2078276048

Land
Großbritannien
Fachdisziplin(en)
Kurzinfo

Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.


Bringing together industry experts, to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression and genome editing


KEYNOTE SPEAKERS

• Ekkehard Leberer, Senior Director, Alliance Management, Sanofi

• Shalini Andersson, Senior Director and Head of New Modalities, AstraZeneca

• Carsten Rudolf, Chief Executive Officer, Ethris Gmbh

• Paul Agris, Founder and Director, The RNA Institute

• Marian Gindy, Executive Director, Pharmaceutical Sciences, Merck Research Labs, Merck and Co

• David Giljohan, CEO, Exicure

• Ingmar Hoerr, Founder and CEO, CureVac AG

• David Blakey, Chief Scientific Officer, MiNA Therapeutics

• André Gerber, Professor of RNA Biology, University of Surrey

• Heinrich Haas, Vice President Drug Delivery, BioNTech RNA Pharmaceuticals

• Markus Mandler, Chief Scientific Officer, Accanis Biotech

• Troels Koch, Vice President and Head of Research, RNA Therapeutics, Roche

• Hans Kistemaker, Associate Director, ProQR


HIGHLIGHTS

- Discover the clinical progress of Spherical Nucleic Acids

- Understand Sanofi’s strategies to deliver therapeutic oligonucleotides across biobarriers

- Learn from ProQR how to plan for oligonucleotide supply from personalized medicine to large scale markets

- Explore the development of small activating RNA – from bench to bedside with MiNA Therapeutics

- Gain insight into the discovery and development of self-amplifying mRNA vaccines at GSK